 |
Pressbox: Evolva Holding SA
- Press release BoxID 148104
Arpida reports progress in pivotal Phase III Trial with TLT treatment in onychomycosis
(PresseBox) Reinach, 22.01.2008, Arpida Ltd. (SWX: ARPN) announced today that patient screening for enrolment into the pivotal Phase III study with the TLT treatment in onychomycosis has been initiated...
Observe this press release
We will be glad to notify you per E-Mail when inactive Press releases are released by the publisher. Observe the corresponding messages:
Company info
Evolva Holding SA
Duggingerstraße 23
CH-4153 Reinach
The specified publisher (see company information at right) is responsible for the above press release. Normally, this is also the author of the press releases, as well as attached image, audio or information material. The unn | UNITED NEWS NETWORK GmbH accepts no responsibility for accuracy, or completeness of the displayed press release. Also, regarding transmission errors or other disorders shall be liable only in cases of willful intent or gross negligence.
The use of archived information for personal and journalistic use is normally free of charge. Please clarify any copyright issues regarding further use of material with the specified publisher. Upon publication, please send a courtesy copy to service@pressebox.de.
A systematic storage of these data as well as the use of a part or the whole of this data base is subject to written appoval by the unn | UNITED NEWS NETWORK GmbH.
The use of archived information for personal and journalistic use is normally free of charge. Please clarify any copyright issues regarding further use of material with the specified publisher. Upon publication, please send a courtesy copy to service@pressebox.de.
A systematic storage of these data as well as the use of a part or the whole of this data base is subject to written appoval by the unn | UNITED NEWS NETWORK GmbH.
